Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation.
Saved in:
| Title: | Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation. |
|---|---|
| Authors: | Tillman L; School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK., Pusztai L; Department of Medicine, Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA., Wander SA; Mass General Brigham Cancer Institute, Boston, MA, USA., Sundar R; Department of Medicine, Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA. Electronic address: raghav.sundar@yale.edu., Klempner SJ; Mass General Brigham Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: sklempner@mgb.org. |
| Source: | Cancer cell [Cancer Cell] 2026 Jun 08; Vol. 44 (6), pp. 1099-1107. Date of Electronic Publication: 2026 May 21. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1878-3686 |
|---|---|
| DOI: | 10.1016/j.ccell.2026.04.011 |
